Ann: Preliminary Final Report, page-11

WOW what a beautiful set of numbers !!!! May I add
(1) EPS increased to 31c which is almost 3x its share price
(2) Cash flow from operations up 327% to $1.62m
(3) NPAT at $1.27m on Sales of $3.62m almost 30% margin !!!
(4) Addition of further 60 hospitals and centers
(5) Clinical trial work won US $1.5m
(6) Cash on hand at 30/06/19 up 99% to $3.1m
It is interesting to note that another AI company RAP sp went up by 30% when it announced approval from EU. Rap has a mc 3X that of RHt and has yet to make a profit ! FDA approval is pending.
I will leave it to you to evaluate which is the preferred company for investment purposes. GLTA